Atherogenic Effect of Homocysteine, a Biomarker of Inflammation and Its Treatment.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and treatments with no primary human data or systematic review methodology
PubMed 39502352 · doi:10.1055/s-0044-1788280
What was done
This narrative review synthesized the pathways of homocysteine synthesis and metabolism, causes of hyperhomocysteinemia, biological mechanisms of homocysteine-induced atherogenesis, and strategies for lowering homocysteine levels.
What was found
The abstract provides no numerical data, effect sizes, or statistical estimates. It qualitatively describes mechanisms of hyperhomocysteinemia-mediated atherosclerosis, including oxidative stress, reduced nitric oxide bioavailability, smooth muscle proliferation, and elevated inflammatory biomolecules (NF-κB, IL-1β, IL-6, IL-8, adhesion molecules, and growth factors). It also notes that B-vitamins (folic acid, B6, B12), omega-3 fatty acids, and cessation of smoking, alcohol, and caffeine lower homocysteine levels.
Why it matters
The paper summarizes the biochemical and inflammatory pathways linking elevated homocysteine to vascular disease and outlines nutritional approaches to lower circulating levels.
Limits
The abstract contains no empirical measurements, sample sizes, or quantitative outcomes. As a narrative review, it lacks systematic search methodology, risk-of-bias evaluation, and evidence evaluating whether lowering homocysteine translates into reduced cardiovascular events in clinical trials.
Cited by
- context Homocysteine drives cardiovascular smooth muscle proliferation and leads to heart attacks.